Why is Piramal Pharma Ltd falling/rising?

Recent Price Performance and Market Context

Piramal Pharma has outperformed the Sensex over the past week and year-to-date periods, with returns of +5.17% and +4.50% respectively, compared to the Sensex’s +0.46% and -0.18% in the same intervals. However, the stock has significantly lagged the benchmark over the last twelve months, delivering a negative return of -27.27% against the Sensex’s robust +9.10%. Over a longer horizon of three years, the stock has outpaced the Sensex, generating a 59.37% return versus the benchmark’s 42.01%. This mixed performance reflects both short-term investor optimism and longer-term concerns about the company’s fundamentals.

On the day in question, the stock underperformed its sector by 0.74%, despite rising for the third consecutive session. Notably, the stock’s price is trading above its 5-day and 20-day moving averages, signalling short-term momentum, but remains below its 50-day, 100-day, and 200-day averages, indicating that medium- and long-term trends are still subdued. Investor participation has increased sharply, with delivery volumes on 05 Jan surging by over 106% compared to the five-day average, suggesting renewed interest from market participants.

Fundamental Strengths Supporting the Stock

Despite recent setbacks, Piramal Pharma exhibits some positive attributes that may be underpinning investor confidence. The company has demonstrated healthy long-term growth, with operating profit expanding at an annualised rate of 23.29%. Its return on capital employed (ROCE) stands at 2.7%, and the enterprise value to capital employed ratio is a modest 2.3, indicating a fair valuation relative to its capital base. Furthermore, the stock trades at a discount compared to its peers’ historical valuations, which could attract value-oriented investors seeking opportunities in the pharmaceutical sector.

Institutional investors hold a significant 45.17% stake in the company, reflecting confidence from entities with the resources and expertise to analyse the company’s fundamentals thoroughly. This institutional backing may be contributing to the recent uptick in share price and trading volumes.

Challenges Tempering Investor Sentiment

However, the company faces considerable headwinds that have weighed on its stock over the past year. Profitability has deteriorated sharply, with profits falling by 158.7% year-on-year. The company’s ability to service its debt is limited, as evidenced by a high Debt to EBITDA ratio of 3.83 times. Net sales growth has been modest at an annual rate of 9.15% over the last five years, which is insufficient to offset the rising debt burden and declining profitability.

Return on equity remains extremely low at an average of 0.32%, signalling poor returns generated for shareholders. The latest quarterly results for September 2025 were particularly disappointing, with profit before tax excluding other income plunging 340% to a loss of ₹111.78 crores, and net profit after tax falling 613% to a loss of ₹99.22 crores. Net sales also declined by 10.5% compared to the previous four-quarter average, underscoring operational challenges.

These negative financial indicators have contributed to the stock’s underperformance relative to the broader market, which has delivered positive returns over the last year. Investors remain cautious given the company’s weak earnings trajectory and high leverage, which may limit upside potential in the near term.

Conclusion: A Stock in Recovery but Facing Structural Challenges

Piramal Pharma Ltd’s recent share price rise on 06-Jan reflects a short-term recovery driven by increased investor participation and relative valuation appeal. The stock’s gains over the past week and year-to-date periods suggest some renewed optimism among investors, possibly supported by institutional interest and the company’s long-term operating profit growth. Nevertheless, the company’s weak recent earnings, high debt levels, and poor return on equity continue to pose significant risks.

Investors should weigh these mixed signals carefully. While the stock shows signs of a potential turnaround, the structural challenges and disappointing quarterly results highlight the need for cautious appraisal. The stock’s performance relative to moving averages and sector peers indicates that any sustained recovery will depend on improved profitability and debt management in the coming quarters.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →